Medicamen Biotech Q2 Results FY27: Revenue Up 10.18% to Rs 46.53 Cr, PAT Rises to Rs 2.35 Cr

Medicamen Biotech Ltd (MEDICAMEQ) Q2 Results FY27 announced on 13 November 2026, covering the company's financial performance for the July to September quarter. The Standalone figures show revenue of Rs 46.53 Cr against Rs 42.23 Cr a year earlier and PAT of Rs 2.35 Cr against Rs 2.21 Cr. This Medicamen Biotech Q2 Results FY27 report is built around that results date and the Standalone results basis.

This Medicamen Biotech Q2 Results results analysis covers the financial highlights, the business drivers, the FY27 outlook and the risks that the disclosed data brings up. The Financial Highlights table that follows places the three profit and revenue lines side by side.

Click Here – Get Free Investment Predictions

Medicamen Biotech Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 46.53 Cr	Rs 42.23 Cr	+10.18% YoY
Operating Profit	Rs 5.92 Cr	Rs 5.05 Cr	+17.23% YoY
Net Profit (PAT)	Rs 2.35 Cr	Rs 2.21 Cr	+6.33% YoY

Source: company filing for Medicamen Biotech Q2 Results FY27, 13 November 2026. Figures in Rs Crore, Standalone basis.

Key Takeaways from Medicamen Biotech Q2 Results: What Stands Out

• Revenue: Medicamen Biotech recorded Rs 46.53 Cr for the quarter, compared with Rs 42.23 Cr in the same period last year, a gain of 10.18%.
• Operating Profit: Operating Profit reached Rs 5.92 Cr from Rs 5.05 Cr a year earlier, an increase of 17.23% on the Standalone basis.
• PAT: Net profit moved from Rs 2.21 Cr to Rs 2.35 Cr in the YoY comparison, which is YoY growth of 6.33%.
• Quarter on quarter: Revenue was up 6.1% quarter on quarter from Rs 43.85 Cr, so the latest figure also sits above the preceding quarter.
• Risk headline: Return on equity was 4.23% in FY26 and return on capital employed was 6.00%, which the performance analysis picks up next.

Medicamen Biotech Q2 Results FY27: Performance Analysis

Standalone revenue of Rs 46.53 Cr was 10.18% above the Rs 42.23 Cr reported a year earlier. Operating Profit rose 17.23% to Rs 5.92 Cr and net profit rose 6.33% to Rs 2.35 Cr. In Medicamen Biotech Q2 Results FY27, all three lines therefore moved higher, with Operating Profit growing fastest.

The Operating Profit line grew faster than revenue, while net profit grew a little slower than revenue. The supplied figures show what changed but not why, so the Key Business Factors section lists only the disclosed drivers. The results analysis for the Medicamen Biotech Q2 Results numbers rests on these three YoY changes.

Looking ahead, investors will track whether the quarterly results continue the revenue pattern and how net profit behaves in later quarters. Revenue was also up 6.1% quarter on quarter from Rs 43.85 Cr, which is a reminder to study YoY growth alongside the individual business factors that follow.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue up 10.2% year on year – The YoY growth story begins with revenue, which grew 10.2% year on year to Rs 46.53 Cr in the latest quarter. Every other line in the Standalone statement sits on top of this larger revenue base.

Net profit up 6.3% year on year – Net profit rose 6.3% year on year to Rs 2.35 Cr from Rs 2.21 Cr. In Medicamen Biotech Q2 Results FY27, this is the slowest growth rate among the three figures supplied for the quarter.

Revenue up 6.1% quarter on quarter – Revenue was up 6.1% quarter on quarter from Rs 43.85 Cr. That comparison gives the latest quarterly results a sequential backdrop without adding any cause beyond what the filing and the supplied data state.

FY27 Outlook After Medicamen Biotech Q2 Results

Full-year FY27 results will depend on the quarters still to be reported and on conditions that are disclosed after the results date. Medicamen Biotech Q2 Results FY27 covers one quarter, with revenue at Rs 46.53 Cr, Operating Profit at Rs 5.92 Cr and net profit at Rs 2.35 Cr.

The results analysis for FY27 will therefore follow how revenue, Operating Profit and net profit develop in later disclosures. Investors can follow those figures in the Univest Screener, and the next section sets out the risks that sit alongside them.

Key Risks to Watch After Medicamen Biotech Q2 Results FY27

Low return on equity

Return on equity was low at 4.23% in FY26. For readers of Medicamen Biotech Q2 Results FY27, this annual figure is a reminder that the quarterly gain sits beside a low full-year return.

Modest return on capital employed

Return on capital employed was modest at 6.00% in FY26. Investors who study YoY growth in profit can compare this balance sheet figure with later disclosures from Medicamen Biotech.

Net profit growth trails revenue

Net profit grew 6.33% YoY while revenue grew 10.18%. The latest reading of Rs 2.35 Cr is therefore the next point of comparison when later quarters are reported.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Medicamen Biotech Q2 Results FY27 report Standalone revenue of Rs 46.53 Cr, Operating Profit of Rs 5.92 Cr and net profit of Rs 2.35 Cr, all higher YoY. Set against low return on equity and modest return on capital employed, these quarterly results give investors both gains and risks to weigh on a Standalone results basis. Please consult a SEBI-registered advisor before acting on this Medicamen Biotech Q2 Results summary.

Frequently Asked Questions on Medicamen Biotech Q2 Results FY27

What are Medicamen Biotech Q2 Results FY27?

Ans. Medicamen Biotech Q2 Results FY27 are the Standalone quarterly results of Medicamen Biotech for July to September 2026. Revenue was Rs 46.53 Cr and net profit was Rs 2.35 Cr, per the Financial Highlights.

What is the results date for Medicamen Biotech Q2 Results FY27?

Ans. Medicamen Biotech declared its results on 13 November 2026, which is the results date for this quarter. Alongside this, the Quick Answer summarises the Standalone revenue, Operating Profit and net profit figures.

What revenue was reported in Medicamen Biotech Q2 Results FY27?

Ans. Medicamen Biotech reported revenue of Rs 46.53 Cr, compared with Rs 42.23 Cr a year earlier, which is why the Financial Highlights table shows a 10.18% YoY change for the top line.

What net profit was reported in Medicamen Biotech Q2 Results FY27?

Ans. Medicamen Biotech Q2 Results FY27 show net profit of Rs 2.35 Cr against Rs 2.21 Cr in the same quarter last year. This comparison is discussed further in the Key Takeaways and Performance Analysis sections.

How much YoY growth did revenue show in Medicamen Biotech Q2 Results FY27?

Ans. Revenue grew 10.18% YoY, rising from Rs 42.23 Cr to Rs 46.53 Cr, so the top line expanded by about a tenth. Performance Analysis explains how this compares with profit growth.

Did net profit rise or fall in Medicamen Biotech Q2 Results?

Ans. Net profit rose in Medicamen Biotech Q2 Results, climbing 6.33% YoY from Rs 2.21 Cr to Rs 2.35 Cr, which means it grew slower than revenue. The Key Business Factors section lists this among the disclosed drivers.

What was the Operating Profit in Medicamen Biotech Q2 Results FY27?

Ans. Operating Profit was Rs 5.92 Cr in the quarter against Rs 5.05 Cr a year earlier, a YoY rise of 17.23%, so it grew faster than revenue. Performance Analysis covers this relationship in detail.

Are Medicamen Biotech Q2 Results consolidated results or standalone results?

Ans. These are Standalone results, so Medicamen Biotech reported the company figures and not group results. This basis applies to every number in the Financial Highlights table and the narrative around it.

What business factors shaped Medicamen Biotech Q2 Results FY27?

Ans. Business factors include revenue growth of 10.2% year on year, net profit growth of 6.3% and revenue that was up 6.1% quarter on quarter. The Key Business Factors section explains each one.

What are the key risks after Medicamen Biotech Q2 Results FY27?

Ans. The risks are return on equity of 4.23% in FY26, return on capital employed of 6.00% and net profit growth that trails revenue growth. Key Risks to Watch covers each of them for readers.

What is the outlook after Medicamen Biotech Q2 Results?

Ans. Full-year FY27 results will depend on later quarters and on disclosed conditions, so investors may follow revenue, Operating Profit and net profit. The Outlook section covers this, and Univest tools carry later updates.

Where can I find the complete Medicamen Biotech Q2 Results FY27 data?

Ans. The complete Medicamen Biotech Q2 Results FY27 figures are in the Financial Highlights table of this article, while the Univest Screener and the Univest app let readers follow the Medicamen Biotech page for later disclosures.